Stocktoria
Camp4 Therapeutics Corp CAMP
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-10-11
Camp4 Therapeutics Corp financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $3.5M | $652,000 | $350,000 |
| R&D expense | $38.2M | $38.8M | $40.6M |
| Operating income | -$52.6M | -$53.1M | -$51.9M |
| Income tax | $0 | $0 | $0 |
| Net income | -$80.4M | -$51.8M | -$49.3M |
| EPS (diluted) | $-2.65 | $-11.04 | $-124.80 |
| Operating cash flow | -$29.6M | -$45.6M | -$44.2M |
| Free cash flow | -$29.8M | -$46.0M | -$44.8M |
| Cash & equivalents | $109.5M | $64.0M | $38.4M |
| Total assets | $117.8M | $78.3M | $54.9M |
| Total liabilities | $70.1M | $15.2M | $16.5M |
| Shareholders' equity | $47.7M | $63.1M | -$123.7M |
Growth · year-over-year · Revenue CAGR 216.1%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +436.5% | +86.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.